OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $13.4286.

Several equities research analysts have recently weighed in on OPRX shares. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Weiss Ratings cut OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, May 14th. Stephens decreased their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, May 13th. UBS Group set a $10.00 price objective on shares of OptimizeRx in a research note on Wednesday, May 13th. Finally, Lake Street Capital lowered their target price on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently modified their holdings of the business. Rhumbline Advisers lifted its holdings in OptimizeRx by 29.9% in the second quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock valued at $487,000 after acquiring an additional 8,297 shares during the period. American Century Companies Inc. boosted its holdings in OptimizeRx by 52.5% during the second quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock worth $325,000 after buying an additional 8,286 shares in the last quarter. Russell Investments Group Ltd. grew its position in OptimizeRx by 141.4% during the second quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock worth $1,493,000 after buying an additional 64,790 shares during the period. Quantbot Technologies LP acquired a new position in OptimizeRx during the second quarter worth about $44,000. Finally, WINTON GROUP Ltd purchased a new position in OptimizeRx in the second quarter valued at about $286,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

Shares of OPRX stock traded up $0.13 during trading hours on Tuesday, hitting $6.41. The stock had a trading volume of 166,535 shares, compared to its average volume of 465,243. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.37 and a quick ratio of 5.37. The firm has a market capitalization of $120.25 million, a PE ratio of 18.31 and a beta of 1.08. The stock’s 50 day moving average is $5.45 and its 200 day moving average is $7.76. OptimizeRx has a twelve month low of $4.54 and a twelve month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. The firm had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.74 million. As a group, research analysts forecast that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.